Full Library

Return to list of results

Hepatitis B Virus Reactivation Potentiated by Biologics

RIS

Recommended format for most reference management software

BibTeX

Recommended format for BibTeX-specific software

Open in Zotero
View on zotero.org
Resource type
Journal Article
Authors/contributors
Title
Hepatitis B Virus Reactivation Potentiated by Biologics
Abstract
Hepatitis B virus (HBV) reactivation can be a serious complication for patients with chronic or resolved HBV infection when treated with biologics. For HBsAg-positive patients receiving biologics, the risk of HBV reactivation is moderate to high. HBsAg-negative/anti-HBc positive patients are at lower risk of HBV reactivation than HBsAg-positive patients. However, patients taking anti-CD20 agents, such as rituximab, have high risk of HBV reactivation (>10%), so antiviral prophylactic therapies are required. This review provides the different classes of biologics associated with HBV reactivation, stratifies the various reactivation risk levels by HBV status and biologic agent, and discusses management strategies.
Publication
Infectious Disease Clinics
Date
2020/06/01
Volume
34
Issue
2
Pages
341-358
Journal Abbr
Infectious Disease Clinics
DOI
10.1016/j.idc.2020.02.009
URL
https://www.id.theclinics.com/article/S0891-5520(20)30011-8/abstract
Accessed
9/1/21, 3:45 PM
ISSN
0891-5520, 1557-9824
Language
English
Library Catalog
www.id.theclinics.com
Extra
Publisher: Elsevier PMID: 32334985
Citation
Ogawa, E., Wei, M. T., & Nguyen, M. H. (2020). Hepatitis B Virus Reactivation Potentiated by Biologics. Infectious Disease Clinics, 34(2), 341–358. https://doi.org/10.1016/j.idc.2020.02.009
ORGANISMS
HEME-ONC AND CELLULAR THERAPIES
Link to this record
https://www.transplantid.net/9WNEYMBM